TONEFITreha: Proof of Concept and Usability Study. (TONFITreha)

TONEFITreha: Proof of Concept and Usability of a Portable Exercise Device to Improve Cardiovascular Functioning and Balance in Neuro-orthopaedic Rehabilitation.

The importance of physical activity and exercise-based interventions in neuro-orthopaedic rehabilitation is undisputed. Yet, patients and clinicians do not implement minimally required doses of physical activity in standard rehabilitation programs. This is partly due to intrinsic factors such as motivation, or due to physical condition that prevent any kind of exercise. In most cases, however, it is owed to limited time spent with therapists who would be able to supervise and apply the required doses to induce any potential exercise effects. Methods to semi-autonomously exercise with high motivation and continuous feedback would complement existing therapies and allow adherence to minimal dose recommendations.

For this study, a prototype of a new portable training solution for intensive walking exercise with built-in sensor-technology and a smartphone interface will be tested regarding its usability and its efficiency in a clinical setting.

Study Overview

• Status: Completed
• Conditions: Orthopedic Disorder; Neurological Disorder
• Intervention / Treatment: Device: TONEFITreha

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Aargau
    • Rheinfelden, Aargau, Switzerland, 4310
      • Reha Rheinfelden

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• In-patients with non-specified pathological background
• At trial centre for at least 2 weeks
• If less than 4 weeks, willingness to visit clinic for the remaining exercise sessions.
• Must be able to walk independently (no or minimal gait impairment)
• Deemed fit for walking group exercise and other exercise (medical expert opinion).
• Cleared for low-intensity endurance exercise by treating physicians and therapists (medical expert opinion).
• Informed Consent as documented by signature (Appendix Informed Consent Form).

Exclusion Criteria:

• Health condition does not allow free movements of body segments (e.g. un-consolidated upper limb fracture)
• Contraindications to low-intensity endurance training (e.g. congestive heart failure, unstable angina, peripheral arterial occlusive disease).
• Fresh wounds around waist and trunk.
• Orthopaedic condition that limits walking ability (e.g. newly operated total hip replacement).
• Women who are pregnant or breast feeding,
• Intention to become pregnant during the course of the study
• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable double-barrier method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, combined with mechanical barriers (e.g. condoms or diaphragms) or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
• Known or suspected non-compliance, drug or alcohol abuse,
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant (derived from medical history),
• Previous enrolment into the current study,
• Enrolment of the investigator, his/her family members, employees and other dependent persons.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Test group

Device: TONEFITreha; The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability	Participants will be asked to rate the perceived usability based on the System Usability Scale (SUS). SUS assesses perceived effectiveness (can users successfully achieve their objectives), information quality (how much effort and resource is expended in achieving those objectives) and general satisfaction (was the experience satisfactory). The SUS hast 10 items that can be rated on a 5-point likert scale. The items will be scored as follows: For odd-numbered items, user response-1. For even-numbered items 5-user response. This scales all values from 0 to 4 (with four being the most positive response). Ref: Jeff Sauro, measuring usability; Add up the converted responses for each user and multiply that total by 2.5 (to convert the range of possible values from 0 to 100 instead of from 0 to 40).; single missing values are replaced with a neutral 3. Normative values will be used to grade the achieved median score (A through D, with D being least acceptable grade).	3-4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability: Assists	Each participant will have a list of tasks to be completed per session. Amount of additional assistance following the introduction (after three supervised sessions), will be counted as outcome. E.g. additional verbal cues or practical assistance.	3-4 weeks
Usability: Completion rate efficiency [%/s]	Each participant will have a list of tasks to be completed per session. mean completion rate/mean task time = completion rate efficiency [%/s]; e.g. 80% completed all tasks within an average of 360 seconds. Task time: mean time taken before training was started [s].	3-4 weeks
Usability: Goal achievement efficiency [%/s]	Each participant will have a list of tasks to be completed per session. mean goal achievement/mean task time = Goal achievement efficiency [%/s]; e.g. 43% completed in 360 seconds Mean goal achievement: Mean extent to which the tasks were completed [%], e.g. 3 out of 7 tasks completed correctly = 43%.	3-4 weeks
Proof-of-Concept: Measurement of covered walking distance with the built-in sensors.	Standardised clinical assessment often employed as part of routine assessments will be used. The 10 Meter Walk Test (10MWT) is a performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function.	At first visit (t+0) and prior to first training 2-4 days after first vist (t+2)
Proof-of-Concept: Gait speed with the built-in sensors.	A second standardised clinical assessment often employed as part of routine assessments will be used. The 6 Minute Walk Test (6MWT) is a sub-maximal exercise test used to assess aerobic capacity and endurance.	At first visit (t+0) and prior to first training 2-4 days after first vist (t+2)
Proof-of-Concept: Increased intensity during walking (VCO2/VO2 relationship)	Cardiopulmonary response will be measured using a breath-by-breath cardiorespiratory monitoring system (MetaMax 3B, Cortex Biophysik, Leipzig, Germany) and a receiver board (HRMI, Sparkfun, Boulder, USA). During 10 meter walk test and a 6-minute walk test, oxygen uptake (VO2) and carbon dioxide output (VCO2) will be recorded and reported and VCO2/VO2 relationship.	At first visit (t+0 days) and prior to first training 2-4 days after first vist (t+2 days)
Proof-of-Concept: Increased intensity during walking (heart rate)	During 10 meter walk test and a 6-minute walk test, heart rate (HR) will be recorded in both conditions (with and without belt). HR will be recorded over a rate belt (T31, Polar Electro, Kempele, Finland).	At first visit (t+0 days) and prior to first training 2-4 days after first vist (t+2 days)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Experience with walking exercises	The amount of experience with walking exercise (qualitative, verbal description or as hours/week, if applicable),	At first visit (t+0 days).
General attitude towards technology based exercise:	- attitude towards technology and the use of sensors (visual analogue scale, VAS, 0 to 100mm, where 0 stands for 'negative attitude' and 100 for 'positive attitude'),	At first visit (t+0 days).
Demographics: Age	Age in years.	At first visit (t+0 days).
Demographics: Weight and height reported as BMI [kg/m^2]	Weight [kg] and height [m] in BMI [kg/m^2]	At first visit (t+0 days).
Demographics: Profession	Profession (qualitative description)	At first visit (t+0 days).
Attrition	For attrition, the number of participants lost during the intervention was recorded. For adherence, participants' engagement with the intervention will be assessed.	3 to 4 weeks after first visit.
Adherence	Adherence will be calculated as the number of completed training sessions as a percentage of the maximal possible training sessions.	3 to 4 weeks after first visit.
Exercise diary:	Training duration and intensity will be derived from the smartphone interface.	3-4 weeks

Collaborators and Investigators

• Sponsor: Reha Rheinfelden
• Investigators: Principal Investigator: Frank A Behrendt, PhD, Reha Rheinfelden

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2018
• Primary Completion (Actual): May 30, 2019
• Study Completion (Actual): November 30, 2019

Study Registration Dates

• First Submitted: June 18, 2018
• First Submitted That Met QC Criteria: July 13, 2018
• First Posted (Actual): July 26, 2018

Study Record Updates

• Last Update Posted (Actual): April 21, 2020
• Last Update Submitted That Met QC Criteria: April 17, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Nervous System Diseases; Musculoskeletal Diseases
• Other Study ID Numbers: 2018-00793

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No